![surpass 6 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial PDF] Early-Onset Type 2 Diabetes](https://www.thelancet.com/cms/asset/96874444-5a73-45b6-bf8b-16e5835720ab/gr2.jpg)
surpass 6 tirzepatide
Shipping Estimate
surpass 6 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial PDF] Early-Onset Type 2 Diabetes
USD28.16
USD63.16
Pay in 4 interest-free payments of $7.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
![surpass 6 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial PDF] Early-Onset Type 2 Diabetes](https://figures.semanticscholar.org/47f2cbae01360a57626762aec4a9f115ff7b6417/6-Figure1-1.png)
![surpass 6 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial PDF] Early-Onset Type 2 Diabetes](https://diabetesonthenet.com/wp-content/uploads/Tirzepatide-iStock-2217097258.jpg)
![surpass 6 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial PDF] Early-Onset Type 2 Diabetes](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=1425010346325638)
![surpass 6 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial PDF] Early-Onset Type 2 Diabetes](https://mms.businesswire.com/media/20231003113775/en/1905467/22/EASD_2023_Image.jpg)
_10mg.png)
